Mohit Bansal
Stock Analyst at Wells Fargo
(4.46)
# 340
Out of 4,761 analysts
156
Total ratings
65.93%
Success rate
13.67%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Equal-Weight | $165 → $140 | $140.64 | -0.46% | 13 | Feb 13, 2025 | |
| JAZZ Jazz Pharmaceuticals | Upgrades: Overweight | $130 → $170 | $136.01 | +24.99% | 2 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $105 → $120 | $109.95 | +9.14% | 10 | Feb 12, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | $60 → $62 | $55.83 | +11.05% | 8 | Feb 7, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $195 → $210 | $202.08 | +3.92% | 7 | Feb 3, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Equal-Weight | $460 | $484.24 | -5.01% | 10 | Jan 30, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,000 → $970 | $873.68 | +11.02% | 16 | Jan 28, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Equal-Weight | $62 → $57 | $57.75 | -1.30% | 6 | Jan 13, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,050 → $900 | $700.33 | +28.51% | 16 | Jan 10, 2025 | |
| AMGN Amgen | Maintains: Equal-Weight | $335 → $280 | $303.01 | -7.59% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $22.12 | +35.62% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $170 | $120.01 | +41.65% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $28.58 | +144.93% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $125 → $110 | $89.50 | +22.91% | 10 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $27 | $21.98 | +22.84% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $90 | $68.25 | +31.87% | 5 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $1.82 | +561.16% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $26.30 | +14.07% | 9 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $140 → $170 | $120.69 | +40.86% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $9.56 | +182.43% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $39.73 | +25.85% | 1 | Nov 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $10.98 | +16,976.50% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $30 | $13.17 | +127.79% | 4 | Jan 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $1.37 | +2,527.74% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $17.30 | +9.83% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $5 | $0.56 | +793.66% | 3 | Apr 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.96 | +2,961.22% | 4 | Dec 3, 2019 |
Biogen
Feb 13, 2025
Maintains: Equal-Weight
Price Target: $165 → $140
Current: $140.64
Upside: -0.46%
Jazz Pharmaceuticals
Feb 13, 2025
Upgrades: Overweight
Price Target: $130 → $170
Current: $136.01
Upside: +24.99%
Gilead Sciences
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $120
Current: $109.95
Upside: +9.14%
Bristol-Myers Squibb Company
Feb 7, 2025
Maintains: Equal-Weight
Price Target: $60 → $62
Current: $55.83
Upside: +11.05%
AbbVie
Feb 3, 2025
Maintains: Overweight
Price Target: $195 → $210
Current: $202.08
Upside: +3.92%
Vertex Pharmaceuticals
Jan 30, 2025
Downgrades: Equal-Weight
Price Target: $460
Current: $484.24
Upside: -5.01%
Eli Lilly and Company
Jan 28, 2025
Maintains: Overweight
Price Target: $1,000 → $970
Current: $873.68
Upside: +11.02%
Halozyme Therapeutics
Jan 13, 2025
Maintains: Equal-Weight
Price Target: $62 → $57
Current: $57.75
Upside: -1.30%
Regeneron Pharmaceuticals
Jan 10, 2025
Maintains: Overweight
Price Target: $1,050 → $900
Current: $700.33
Upside: +28.51%
Amgen
Jan 10, 2025
Maintains: Equal-Weight
Price Target: $335 → $280
Current: $303.01
Upside: -7.59%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $22.12
Upside: +35.62%
Dec 11, 2024
Initiates: Overweight
Price Target: $170
Current: $120.01
Upside: +41.65%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $28.58
Upside: +144.93%
Nov 1, 2024
Maintains: Equal-Weight
Price Target: $125 → $110
Current: $89.50
Upside: +22.91%
Oct 21, 2024
Upgrades: Overweight
Price Target: $9 → $27
Current: $21.98
Upside: +22.84%
Sep 17, 2024
Maintains: Overweight
Price Target: $115 → $90
Current: $68.25
Upside: +31.87%
Aug 9, 2024
Maintains: Overweight
Price Target: $14 → $12
Current: $1.82
Upside: +561.16%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $26.30
Upside: +14.07%
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $120.69
Upside: +40.86%
Mar 7, 2023
Initiates: Overweight
Price Target: $27
Current: $9.56
Upside: +182.43%
Nov 28, 2022
Initiates: Overweight
Price Target: $50
Current: $39.73
Upside: +25.85%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $10.98
Upside: +16,976.50%
Jan 7, 2021
Maintains: Buy
Price Target: $25 → $30
Current: $13.17
Upside: +127.79%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $1.37
Upside: +2,527.74%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $17.30
Upside: +9.83%
Apr 27, 2020
Maintains: Buy
Price Target: $8 → $5
Current: $0.56
Upside: +793.66%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.96
Upside: +2,961.22%